JLE

Epileptic Disorders

MENU

Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy Volume 6, issue 4, December 2004

1 Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-99.

2 Prasad A, Kuzniecky RI, Knowlton RC, et al. Evolving anti-epileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 2003; 60: 1100-5.

3 Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neurol 2002; 17: 87-96.

4 Renganathan R, Delanty N. Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed. Postgrad Med J 2003; 79: 78-80.

5 Gelisse P, Genton P, Thomas P, et al. Clinical factors of drug resistance in juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 2001; 70: 240-3.

6 Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channels in cultured neurons of rat cerebral cortex. Epilepsy Res 1992; 12: 21-7.

7 Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 1998; 20: 593-7.

8 Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy or polytherapy. Epilepsia 1982; 23: 693-720.